Global /China /Industrials /Specialty Business Services /688202
chevron_leftBack
Shanghai Medicilon Inc. logo

Shanghai Medicilon Inc.

688202
SSE: 688202 Delayed
63.26CNY -3.8%
9.35 USD
As of 15 June 2026, Shanghai Medicilon Inc. has a market cap of $1.28B USD, ranking #9332 globally and #2502 in China. It ranks #2054 in the Industrials sector, and #181 in the Specialty Business Services industry.
Global Rank
9332
Country Rank
2502
Sector Rank
2054
Industry Rank
181
Key Stats
Market Cap
$1.28BUSD
8.65B CNY
Enterprise Value
$1.23BUSD
8.33B CNY
Revenue (TTM)
$171.64MUSD
1.16B CNY
EBITDA (TTM)
-$13.85MUSD
-93.71M CNY
Net Income (TTM)
-$24.77MUSD
-167.83M CNY
EBITDA Margin
-8.1%
Profit Margin
-14%
PS Ratio
7.4
PB Ratio
4.5
Company Profile
Country (HQ)
Sector
Industrials
Industry
Specialty Business Services
CEO
Chunlin Chen open_in_new
Employees
1,717
Founded
2004
Website
medicilon.com.cn open_in_new
warningChart data may be delayed
1d 1w 1m 3m 6m 1y
-3.8% -6.3% 9% 12% -4.1% 133%

News

Loading...

Markets

Exchange Ticker Price
Shanghai Stock Exchange
MIC: XSHG
PRIMARY
688202
上海美迪西生物医药股份有限公司 Class A
ISIN: CNE100003NQ8
Shares Out.:
132.027M1 Shares Float: 59.733M2
TV:
SA:
YF:
GF:
BA:
MS:
63.26 CNY
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.

About Shanghai Medicilon Inc.

Shanghai Medicilon Inc., a contract research organization, provides drug discovery and development services to pharmaceutical and biotechnology companies in China and internationally. The company operates in Drug Discovery and Pharmaceutical Research, and Preclinical Research segments. It offers medicinal and analytical chemistry; process development; custom and zoom in synthesis; structural, in vitro, and computational biology; protein expression and purification; protein crystallization; and recombinant kinase preparation services, as well as protein target validation, compound activity screening and optimization, raw material and preparation process research, and quality standards and stability research services. The company also provides process route screening, API production process optimization, drug process research and application, pharmacology services, drug safety evaluation, biological analysis, IND filing, and TCM preclinical trial service solutions, such as pharmaceutical research, pharmacodynamics, pharmacokinetics, and toxicology. In addition, it offers lipid synthesis, liposome preparation, prescription screening, process optimization and development, quality research, safety evaluation, bioanalysis, registration and declaration, etc.; pre-formulation research, drug analysis, drug stability research, and formulation development; and cytokine and biomarker testing, bioanalysis, and flow cytometry service, as well as engages in the research and development of new drugs. Further, the company is involved in the molecular drug development business. The company was founded in 2004 and is based in Shanghai, China.

Similar Companies

Industry: Specialty Business Services (China)
Name
Market Cap diff.
PE
$9.42B
73.79B HKD
638%
47.0
$8.76B
59.36B CNY
586%
296.1
$6.6B
417%
11.8
$6.25B
42.34B CNY
389%
480.6
$4.62B
31.29B CNY
262%
128.4
$4.6B
31.16B CNY
260%
163.3
Industry: Specialty Business Services (Global)
Name
Market Cap diff.
PE
SHOP
$158.14B
12K%
129.8
VSURE
$132.68B
114.8B EUR
10K%
-
CTAS
$69.6B
5K%
36.8
REL
$63.78B
47.6B GBP
5K%
23.9
PYPL
$45.83B
3K%
9.4
$41.8B
56.91B CAD
3K%
-
chevron_leftBack